Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)

References

• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358: 903–11.
   PubMed Web of Science ®Google Scholar
• Hakoda M, Oiwa H, Kasagi F, Masunari N, Yamada M, Suzuki G, et al. Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study. Ann Rheum Dis. 2005;64:1451–5.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328–46.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370: 1861–74.
   Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.
   PubMed Web of Science ®Google Scholar
• Salfeld J, Kaymakçalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum. 1998;41(Suppl 9):557.
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508–16.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50: 1400–11.
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol. 2003;30:2563–71.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pav-elka K, van Vollenhoven R, et al. The PREMIER study: a mul-ticenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
   Google Scholar
• Miyasaka N, Takeuchi T, Eguchi K. Proposed [corrected] Japa-nese Guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol. 2005;15:4–8.
   Google Scholar
• Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16:63–7.
   PubMedGoogle Scholar
• Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28–32.
   PubMedGoogle Scholar
• Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol. 2008;18:146–52.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Itcari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruc-tion (RECONFIRM-2J). Mod Rheumatol. 2008;18:447–54.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Kawakami A, Fujikuwa K, Aramaki T, Kawashiri S, Tamai M, et al. Prediction of DA528-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol. 2009;19:488–92.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, the CHANGE Study Investigators. Clinical inves-tigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evalua-tion: the CHANGE study. Mod Rheumatol. 2008;18:252–62.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Japan College of Rheumatology. Guidelines for adalimumab (in Japanese). 2008. http://www.ryumachi-jp.com/info/guideline_ ADA.pdf
   Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
   Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137–45.
   PubMed Web of Science ®Google Scholar
• van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261–3.
   PubMed Web of Science ®Google Scholar
• Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol. 1993;20:561–5.
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Prescribing information for Humira® (ada-limumab). Chicago: Abbott Laboratories; 2010.
   Google Scholar
• Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6: 644–52.
   PubMed Web of Science ®Google Scholar
• Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the registry of Japanese rheumatoid arthritis patients for long-term safety. J Rheumatol. 2011. doi: 10.3899/jrheum.101009.
   Google Scholar
• Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21:122–33.
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L, BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observa-tional study of 488 patients over a four-year period. Arthritis Res 'Ther. 2006;8:R29.
   Google Scholar
• Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infiiximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res 'Ther. 2006;8:R174.
   Google Scholar
• Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhib-itor use in 9074 patients with rheumatoid arthritis. J Rheumatol. 2009;36:907–13.
   PubMed Web of Science ®Google Scholar
• Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DPM, Hyrich KL, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheu-matology Biologics Register. Ann Rheum Dis. 2011;70:583–9.
   PubMed Web of Science ®Google Scholar